These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8827586)

  • 1. Towards a practical strategy for assessing individual bioequivalence. Food and Drug Administration Individual Bioequivalence Working Group.
    Schall R; Williams RL
    J Pharmacokinet Biopharm; 1996 Feb; 24(1):133-49. PubMed ID: 8827586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual bioequivalence revisited.
    Chen ML; Lesko LJ
    Clin Pharmacokinet; 2001; 40(10):701-6. PubMed ID: 11707058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An individual bioequivalence criterion: regulatory considerations.
    Chen ML; Patnaik R; Hauck WW; Schuirmann DJ; Hyslop T; Williams R
    Stat Med; 2000 Oct; 19(20):2821-42. PubMed ID: 11033578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing bioequivalence and drug interchangeability.
    Chen M; Chow SC
    J Biopharm Stat; 2017; 27(2):272-281. PubMed ID: 27936343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New bioequivalence studies: individual bioequivalence and population bioequivalence.
    Nakai K; Fujita M; Ogata H
    Yakugaku Zasshi; 2000 Nov; 120(11):1201-8. PubMed ID: 11190205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On TIER method for assessment of individual bioequivalence.
    Ju HL
    J Biopharm Stat; 1997 Mar; 7(1):63-85. PubMed ID: 9056589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On population and individual bioequivalence.
    Schall R; Luus HG
    Stat Med; 1993 Jun; 12(12):1109-24. PubMed ID: 8210816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration.
    Hauck WW; Hyslop T; Chen ML; Patnaik R; Williams RL
    Pharm Res; 2000 Apr; 17(4):375-80. PubMed ID: 10870978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin.
    Yacobi A; Masson E; Moros D; Ganes D; Lapointe C; Abolfathi Z; LeBel M; Golander Y; Doepner D; Blumberg T; Cohen Y; Levitt B
    J Clin Pharmacol; 2000 Aug; 40(8):826-35. PubMed ID: 10934666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring switchability and prescribability: when is average bioequivalence sufficient?
    Hauck WW; Anderson S
    J Pharmacokinet Biopharm; 1994 Dec; 22(6):551-64. PubMed ID: 7473081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical evaluation of the scaled criterion for drug interchangeability.
    Li J; Chow SC
    J Biopharm Stat; 2017; 27(2):282-292. PubMed ID: 27937059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consideration of individual bioequivalence.
    Anderson S; Hauck WW
    J Pharmacokinet Biopharm; 1990 Jun; 18(3):259-73. PubMed ID: 2380920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levothyrox
    Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran A; Toutain PL
    Clin Pharmacokinet; 2019 Jul; 58(7):827-833. PubMed ID: 30949873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Types of bioequivalence and related statistical considerations.
    Hauck WW; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers.
    Kim JE; Ki MH; Yoon IS; Cho HJ; Kim RS; Tae Kim G; Kim DD
    Clin Ther; 2014 Feb; 36(2):273-9. PubMed ID: 24529292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.